Pharmacology of insulin detemir.

Article Details

Citation

Copy to clipboard

Kurtzhals P

Pharmacology of insulin detemir.

Endocrinol Metab Clin North Am. 2007 Aug;36 Suppl 1:14-20.

PubMed ID

17881328 [ View in PubMed

]

Abstract

Insulin detemir (Levemir [Novo Nordisk A/S, Bagsvaerd, Denmark]) is a soluble, long-acting basal insulin analog. It differs from human insulin in that the amino acid threonine in position B30 has been removed and a 14-carbon fatty acid (myristic acid) has been acylated to lysine at B29. This modification increases self-association and enables albumin binding of insulin detemir. In this manuscript, the unique molecular properties and the resulting pharmacodynamics of insulin detemir are reviewed. The protracted duration of action, smooth activity profile, and low intrapatient variability of insulin detemir are presented as properties that may potentially help patients maximize glycemic control and minimize the long-term complications of diabetes.

DrugBank Data that Cites this Article

Drugs

Insulin detemir

Drug Carriers

Drug	Carrier	Kind	Organism	Pharmacological Action	Actions
Insulin detemir	Serum albumin	Protein	Humans	No	Binder	Details